Comparison of Hemospray® and Endoclot™ for the treatment of gastrointestinal bleeding

doi:10.3748/wjg.v25.i13.1592

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8713)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

700

WORD

199

HTML

5873

Figures (1-3)

249

Tables (1-4)

149

Sum=7170

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

814

Download

729

Sum=1543

Apr 7, 2019 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Apr 7, 2019; 25(13): 1592-1602
Published online Apr 7, 2019. doi: 10.3748/wjg.v25.i13.1592

Table 1 Clinical characteristics of the total patient cohort treated with hemostatic powders for gastrointestinal bleeding n (%)

	HS and EC n = 154	Hemospray n = 111	Endoclot n = 32	P value
Sex (M)	101 (65.6)	76 (68.5)	17 (53.1)	NS
Age, yr
mean ± SD	66.6 ± 14	67 ± 13.8	67.4 ± 15.1	NS
range	11-93	29-93	11-89
Rockall risk score
median ± SD	7.1 ± 1.7	7.1 ± 1.7	7.1 ± 1.8	NS
range	2-10	2-10	2-10
Comorbidities
Coagulopathy	48 (31.2)	36 (32.4)	6 (18.8)	NS
Renal insufficiency	74 (48.1)	53 (47.7)	15 (46.9)	NS
Hemodialysis	35 (22.7)	26 (23.4)	5 (15.6)	NS
Liver cirrhosis	40 (26)	32 (28.9)	5 (15.6)	NS
Bleeding locale
upper GI bleeding	137 (89)	102 (91.8)	25 (78.1)	0.04
lower GI bleeding	17 (11)	8 (8)	7 (21)	NS
Application as
Primary therapy	82 (53.2)	64 (57.7)	14 (43.8)	NS
Salvage therapy	72 (46.8)	47 (42)	18 (56)	NS
Multiple applications of HP	42 (27.3)	27 (24.3)	5 (15.6)	NS
Definite hemostatic therapies after HP failure
Coiling	13 (8.4)	11 (9.9)	1 (3.1)	NS
Surgery	9 (5.8)	7 (6.3)	1 (3.1)	NS
Short term success (total)	125 (81.2)	92 (82.9)	26 (81.2)	NS
Primary therapy	67/82 (81.7)	53/64 (82.8)	11/14 (78.6)
Salvage therapy	58/72 (80.6)	39/47 (82.9)	15/18 (83.3)
Long term success	81/121 (66.9)	59 (69.4)	18 (66.7)	NS
Primary therapy	45/65 (69.2)	35/49 (71.4)	8/13 (61.5)
Salvage therapy	36/56 (64.3)	24/36 (66.7)	10/14 (71.4)
Re-bleeding rate	41 (26.6)	27 (24.3)	8 (25)	NS
Primary therapy	18/82 (21.9)	13/64 (20.3)	3/14 (21.4)
Salvage therapy	23/72 (31.9)	14/47 (29.8)	5/18 (27.8)

HS: Hemospray; EC: Endoclot; HP: Hemostatic powders; HS and EC: Including patients who received both Hemospray and Endoclot at different time points; NS: Not specified; GI: Gastrointestinal.

Table 2 Clinical characteristics of the patients with upper gastrointestinal bleeding and efficacy of hemostatic powders in the treatment of upper gastrointestinal bleeding n (%)

	HS and EC (n = 137)	Hemospray (n = 102)	Endoclot (n = 25)	P value
Sex (M)	86 (62.8)	68 (66.7)	11 (44)	0.04
Age, yr
mean ± SD	66.4 ± 14.2	66.4 ± 14.0	67.9 ± 16.5	NS
range	(11-93)	29-93	11-89
Rockall risk score				NS
median ± SD	7.1 ±1.7	7.1 ± 1.7	7.1 ± 1.8
range	2-10	2 -10	2 - 10
Comorbidities
Coagulopathy	45 (32.8)	34 (33)	5 (2)
Renal insufficiency	68 (49.6)	59 (49)	12 (48)
Hemodialysis	32 (23.4)	24 (23)	12 (48)
Liver cirrhosis	38 (27.7)	30 (29.4)	5 (20)
Therapeutic anticoagulation	35 (25.5)	28 (27.5)	6 (24)
Dual antiplatet therapy	7 (5.1)	5 (5)	2 (8)
Vitamin K antagonists	14 (10.2)	11 (11)	3 (12)
DOAC	8 (5.8)	7 (7)	1 (4)
Antiaggregation therapy	29 (21.2)	21 (20.6)	7 (28)
Application as				NS
Primary Therapy	72 (52.6)	59 (58)	10 (40)
Salvage Therapy	65 (47.4)	43 (42)	15 (60)
Multiple Applications of				NS
HS	37 (27)	24 (23)	3 (0.12)
Definite hemostatic therapies after HP failure				NS
Coiling	13 (9.5)	11 (11)	1 (4)
Surgery	8 (5.8)	7 (6.9)	0
Short term success (total)	113/137 (82.5)	68/102 (66.6)	21/25 (84)	NS
Primary therapy	60/72 (83.3)	50/59 (84.7)	8/10 (80)
Salvage therapy	53/65 (81.5)	36/43 (83.7)	13/15 (86.6)
Long term success	71/108 (65.7)	53/78 (67.9)	15/22 (68.2)	NS
Primary therapy	39/57 (68.4)	32/45 (71)	6/10 (60)
Salvage therapy	32/51 (62.7)	21/33(63.6)	9/12 (75)
Re-bleeding rate	34/137 (24.8)	24/102 (23.5)	4/25 (16)	NS
Primary therapy	15/72 (20.8)	11/59 (18.6)	2/10 (20)
Salvage therapy	19/65 (29.2)	13/43 (30.2)	2/15 (13)

DOAC: Direct acting oral anticoagulant; HS: Hemospray; EC: Endoclot; HP: Hemostatic powders; NS: Not specified; HS and EC: Including patients who received both Hemospray and Endoclot at different time points.

Table 3 Etiology of upper gastrointestinal bleeding and success in bleeding management (short term, long term, re-bleeding rate)

	HS and EC (n = 137)	Hemospray (n = 102)	Endoclot (n = 25)
Reflux esophagitis, n	17	16	1
Overall ST, LT, RBR (%)	92, 60, 0	100, 33, 0	100, 0, 0
Primary ST, LT, RR (%)	100, 100, 0	100, 100, 0	0
Salvage ST, LT, RR (%)	100, 100, 0	100, 100, 0	100, 0, 0
OG variceal disease, n	13	11	2
Overall ST, LT, RBR (%)	85, 56, 38	91, 50, 45	100, 100, 0
Primary ST, LT, RBR (%)	75, 25, 75	66, 66, 100	100, 100, 0
Salvage ST, LT, RBR (%)	100, 80, 22	100, 80, 25	100, 0, 0
Peptic ulcer disease, n	49	34	12
Overall ST, LT, RBR (%)	80, 57, 34	80, 59, 29	84, 50, 31
Primary ST, LT, RBR (%)	79, 67, 21	81, 71, 18	75, 50, 25
Salvage ST, LT, RBR (%)	81, 67, 46	78, 40, 50	90, 62,3 0
Angiodysplasia, -ectasia, n	8	6	1
Overall ST, LT, RBR (%)	75, 85, 0	66, 80, 0	100, 100,0
Primary ST, LT, RBR (%)	75, 100, 0	75, 100, 0	0
Salvage ST, LT, RBR (%)	75, 75, 0	50, 50, 0	100, 100, 0
Diffuse bleeding and erosions, n	22	16	4
Overall ST, LT, RBR (%)	77, 72, 36	87, 84, 25	66, 66, 33
Primary ST, LT, RBR (%)	78, 67, 33	100, 100, 0	75, 50, 25
Salvage ST, LT, RBR (%)	66, 70, 58	71, 66, 57	100, 50, 50
Cancer bleeding, n	15	12	1
Overall ST, LT, RBR (%)	81, 85, 10	85, 92, 10	100, 100, 0
Primary ST, LT, RBR (%)	100, 100, 0	100, 100, 0	100, 100, 0
Salvage ST, LT, RRB (%)	67, 50, 0	67, 75, 17	0
Other bleeding sources, n	13	7	4
Overall ST, LT, RBR (%)	70, 70, 40	75, 58, 58	86, 75, 28
Primary ST, LT, RBR (%)	62, 60, 50	50, 43, 62	80, 67, 20
Salvage ST, LT, RBR (%)	77, 69, 36	100, 100, 0	100, 75, 30

Other bleeding sources: Mallory Weiss lesions, aortoduodenal fistula, posttraumatic, bleeding after surgery, anastomosis bleeding. ST: Short term success; LT: Long term success; RBR: Re-bleeding rate; OG: Oesophageal and gastric; HS and EC: Including patients who received both Hemospray and Endoclot at different time points.

Table 4 Clinical characteristics of the patients treated with Hemospray and Endoclot for lower gastrointestinal bleeding n (%)

	HS and EC (n = 17)	Hemospray (n = 9)	Endoclot (n = 7)	P value
Sex (M)	15	8	6	ns
Age, yr				0.007
mean ± SD	67.8 ± 12.2	72.9 ± 9.2	65.6 ± 9.2
range	37-81	51-81	37-76
Application as				ns
Primary therapy	10 (59)	5 (55)	4 (57.1)
Salvage therapy	7 (41.2)	4 (44)	3 (56)
Definite therapy after HP failure				ns
Coiling	0	0	0
Surgery	1 (5.9)	0	1 (14)
Comorbidities
Coagulopathy	3 (17.6)	2 (22)	1 (14)
Renal insufficiency	6 (35.3)	3 (33)	3 (43)
Hemodialysis	3 (17.6)	2 (22)	1 (14)
Liver cirrhosis	2 (11.8)	2 (22)	0
Therapeutic anticoagulation	10 (59)	3 (33)	6 (86)
Dual antiplatet therapy	1 (5.9)	0	1 (43)
Vitamin K Antagonists	3 (17.6)	0	3 (43)
DOAC	3 (17.6)	0	2 (29)
Antiaggregation therapy	5 (29.4)	2 (22)	3 (43)
Short term success	12 (79.6)	6 (67)	5 (71)	ns
Primary therapy	7 (70)	3/5 (60)	3/4 (75)
Salvage therapy	5 (71.4)	3/4 (75)	2/3 (67)
Long term success	10 (76.9)	6/7 (86)	3/5 (75)	ns
Primary therapy	6 (75)	3/4(75)	2/3 (67)
Salvage therapy	4 (57.1)	3/3 (100)	1/2 (50)
Re-bleeding rate	7 (41.2)	3 (33)	4 (57)	ns
Primary therapy	3 (30)	2/5 (40)	1/4 (25)
Salvage therapy	4 (57.1)	1/4 (25)	3/3 (100)

DOAC: Direct acting oral anticoagulant; HS: Hemospray; EC: Endoclot; HP: Hemostatic powders; HS and EC: Including patients who received both Hemospray and Endoclot at different time points.

Citation: Vitali F, Naegel A, Atreya R, Zopf S, Neufert C, Siebler J, Neurath MF, Rath T. Comparison of Hemospray^® and Endoclot^™ for the treatment of gastrointestinal bleeding. World J Gastroenterol 2019; 25(13): 1592-1602
URL: https://www.wjgnet.com/1007-9327/full/v25/i13/1592.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i13.1592